RxDoctor Payments Data

Allen Cooke, NP

Family · Summerville, SCNPI 1851909162

Payments from drug & device makers

$6,917in general payments, 2019–2025

Across 305 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$487
  • Amgen$344
  • Lilly USA, LLC$220
  • Biohaven Pharmaceutical Holding Company Ltd.$218
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,892100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,917 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$78,936
Medicare patients
228
Services billed
1,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$79,498
JardianceEmpagliflozin63$75,515
EliquisApixaban58$56,626
JanuviaSitagliptin Phosphate44$55,562
OzempicSemaglutide18$39,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,979
MounjaroTirzepatide20$19,014
XareltoRivaroxaban23$17,298
Repatha SyringeEvolocumab16$13,686
RybelsusSemaglutide14$13,506
LokelmaSodium Zirconium Cyclosilicate11$9,651
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,561
Atorvastatin Calcium368$2,921
Omeprazole147$2,297
Albuterol Sulfate HfaAlbuterol Sulfate65$1,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,105$89,14993 claims
Boehringer IngelheimJardiance$178$75,51563 claims
PfizerEliquis$165$56,62658 claims
MerckJanuvia$16$55,56244 claims
Novo NordiskOzempic, Rybelsus$487$53,16932 claims
GSKTrelegy Ellipta$202$29,97932 claims
Lilly USA, LLCMounjaro$220$19,01420 claims
Johnson & JohnsonXarelto$181$17,29823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →